- ►nih.gov L Michalik, W Wahli - Journal of Clinical Investigation, 2006 - Am Soc Clin Investig Tissue damage resulting from chemical, mechanical, and biological injury, or
from interrupted blood flow and reperfusion, is often life threatening. The
subsequent tissue response involves an intricate series of events including ... Cited by 80 - Related articles - BL Direct - All 10 versions
CJ Yao, GM Lai, CF Chan, AL Cheng, YY … - International Journal of Cancer, 2006 - interscience.wiley.com Lovastatin (an HMG-CoA reductase inhibitor) and troglitazone (a PPAR- agonist)
have been intensively studied prospectively for their application in cancer
treatment. However, clinical trials of lovastatin or troglitazone in cancer ... Cited by 32 - Related articles - BL Direct - All 5 versions
- ►oxfordjournals.org PK Chatterjee, NSA Patel, S Cuzzocrea, PAJ … - Cardiovascular research, 2004 - cardiovascres.oxfordjournals.org Renal ischemia (I) is a major cause of acute renal failure (ARF), which despite
significant advances in critical care medicine, remains a major clinical
problem, producing grave morbidity and mortality that has not decreased ... Cited by 30 - Related articles - All 7 versions
- ►physiology.org Y Xu, M Gen, L Lu, J Fox, SO Weiss, RD … - American Journal of Physiology- Heart and Circulatory …, 2005 - Am Physiological Soc Peroxisome proliferator-activated receptor (PPAR)- modulates substrate
metabolism and inflammatory responses. In experimental rats subjected to
myocardial ischemia-reperfusion (I/R), thiazolidinedione PPAR- activators ... Cited by 29 - Related articles - All 4 versions
H Hasegawa, H Takano, Y Zou, Y Qin, K … - Journal of molecular and cellular cardiology, 2005 - Elsevier Results – Cardiac dysfunction and remodeling were inhibited in Group P
compared to Group E. Heart weight/body weight ratio and the degree of
inflammation and fibrosis were significantly lower in Group P than in Group ... Cited by 26 - Related articles - All 6 versions
AT Gonon, A Bulhak, F Labruto, PO Sjöquist, … - Basic research in cardiology, 2007 - Springer A. Gonon, MD, PhD ( ) · A. Bulhak · PO Sjöquist · J. Pernow Dept. of
Cardiology Karolinska University Hospital, Solna 17176 Stockholm, Sweden Tel.:
+46-8/517-73560 Fax: +46-87311-040 E-Mail: adrian.gonon@medks.ki.se F. ... Cited by 26 - Related articles - BL Direct - All 4 versions
- ►cardiovascres.org G Ding, M Fu, Q Qin, W Lewis, HW Kim, T … - Cardiovascular Research, 2007 - cardiovascres.org Results PPAR null mice exhibited pathological changes around 3 months of age,
featuring progressive cardiac hypertrophy with mitochondrial oxidative damage.
Most mice died from dilated cardiomyopathy. Cardiac expression of Sod2 ... Cited by 21 - Related articles - All 4 versions
R Qayyum, P Schulman - Diabetes/Metabolism Reviews - interscience.wiley.com Thiazolidinediones, used for the treatment of diabetes mellitus type 2, modulate
gene expression by binding to nuclear transcription factor, peroxisome
proliferator-activated receptor-gamma. Peroxisome proliferator-activated ... Cited by 18 - Related articles - BL Direct - All 3 versions
Y Naito, T Yoshikawa - Drugs of Today, 2004 - journals.prous.com Synthetic peroxisome proliferator-activated receptor γ (PPAR-γ) ligands shown
to induce adipocyte differentiation and increase insulin sensitivity,
thiazolidinediones have recently been implicated as regulators of cellular ... Cited by 10 - Related articles - All 4 versions
PJH Smeets, A Planavila, GJ Van der Vusse, … - Acta Physiologica, 2007 - interscience.wiley.com Peroxisome proliferator-activated receptors (PPARs) are ligand-activated
transcription factors acting as key regulators of lipid metabolism as well as
modulators of inflammation. The role of PPARα and PPARγ in cardiac ... Cited by 8 - Related articles - BL Direct - All 5 versions
